Drugs / PANULISIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01762410 | Sep 2012 → Nov 2015 | refractory malignant neoplasm | Piramal Enterprises Limited | Suspended | No outcome recorded Stop: Business |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PANULISIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095025 ↗ |
| Known as | P7170 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01762410 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase receptor R3 inhibitor” CHEMBL5095025 ↗2“Serine/threonine-protein kinase mTOR inhibitor” CHEMBL5095025 ↗ “PI3K/mTOR inhibitor P7170” NCT01762410 ↗ |
| Modality | Small molecule | — CHEMBL5095025 ↗ |
| Route | Oral | “oral PI3K/mTOR inhibitor P7170” NCT01762410 ↗ |
| Target | ACVRL1 | “Serine/threonine-protein kinase receptor R3 inhibitor” CHEMBL5095025 ↗ |
| Target | MTOR | “Serine/threonine-protein kinase mTOR inhibitor” CHEMBL5095025 ↗ |